Demirci Umut, Ozdemir Nuriye, Benekli Mustafa, Babacan Nalan Akgul, Cetin Bulent, Baykara Meltem, Coskun Ugur, Zengin Nurullah, Buyukberber Suleyman
Ataturk Education and Research Hospital, Ankara, Turkey.
Asian Pac J Cancer Prev. 2012;13(1):383-6. doi: 10.7314/apjcp.2012.13.1.383.
Cancer survivors are at increased risk of second cancers. Lymphoproliferative disorders (LPD) are common neoplasms that are primary or subsequent cancers in cases of multiple primary cancer. We here analyzed metachronous or synchronous LPD in multiple primary cancers.
Between 2001 and 2010, LPD were assessed retrospectively in 242 multiple primary cancers patients.
Forty nine (20.2%) patients with LPD were detected. Six patients had two LPD where one patient had three LPD. The median age of patients was 60.5 years (range: 28-81). LPD were diagnosed in 29 patients as primary cancer, in 23 patients as second cancer, and in three patients as third cancer in multiple primary cancers. Primary tumor median age was 56 (range: 20-79). Diffuse large B cell lymphoma (n=16), breast cancer (n=9), and lung cancer (n=6) were detected as subsequent cancers. Alklylating agents were used in 19 patients (43.2%) and 20 patients (45.5%) had received radiotherapy for primary cancer treatment. The median follow-up was 70 months (range: 7-284). Second malignancies were detected after a median of 51 months (range: 7-278), and third malignancies with a median of 18 months (range: 6-72).
In this study, although breast and lung cancer were the most frequent detected solid cancers in LPD survivors, diffuse large B cell lymphoma was the most frequent detected LPD in multiple primary cancers.
癌症幸存者患第二种癌症的风险增加。淋巴增殖性疾病(LPD)是常见的肿瘤,在多原发性癌症病例中可为原发性或继发性癌症。我们在此分析了多原发性癌症中的异时性或同时性LPD。
2001年至2010年期间,对242例多原发性癌症患者的LPD进行回顾性评估。
检测到49例(20.2%)患有LPD的患者。6例患者有两种LPD,其中1例患者有三种LPD。患者的中位年龄为60.5岁(范围:28 - 81岁)。在多原发性癌症中,29例患者的LPD被诊断为原发性癌症,23例患者的LPD被诊断为第二种癌症,3例患者的LPD被诊断为第三种癌症。原发性肿瘤的中位年龄为56岁(范围:20 - 79岁)。弥漫性大B细胞淋巴瘤(n = 16)、乳腺癌(n = 9)和肺癌(n = 6)被检测为继发性癌症。19例患者(43.2%)使用了烷化剂,20例患者(45.5%)接受了原发性癌症治疗的放疗。中位随访时间为70个月(范围:7 - 284个月)。第二种恶性肿瘤在中位51个月(范围:7 - 278个月)后被检测到,第三种恶性肿瘤在中位18个月(范围:6 - 72个月)后被检测到。
在本研究中,尽管乳腺癌和肺癌是LPD幸存者中最常检测到的实体癌,但弥漫性大B细胞淋巴瘤是多原发性癌症中最常检测到的LPD。